Results 211 to 220 of about 18,175 (274)

Proteolytic Activities and Immunological Effects of Light Chains of Botulinum Neurotoxin A1, A2 and A3 Subtypes. [PDF]

Toxins (Basel)
Liao Y, Hu X, Wang J, Lu J, Yu S, Yu Y, Wu W.   +6 more
europepmc   +1 more source

Updates on the Proposed Botulinum Toxin A Mechanisms of Action in Orofacial Pain: A Review of Animal Studies. [PDF]

Toxins (Basel)
Fabillar J, Yamamoto Y, Koike K, Ikutame D, Matsuka Y.   +4 more
europepmc   +1 more source

Botulinum Neurotoxin A Injections in Spasmodic Entropion: A Clinical Retrospective Cohort Study. [PDF]

Toxins (Basel)
Girard B, Carré F, Begnaud S.
europepmc   +1 more source

New Drugs: Botulinum toxin type A

Australian Prescriber, 1994
openaire   +1 more source

Botulinum Toxin and Redress in the United Kingdom, Findings From a Cross-Sectional Survey. [PDF]

J Cosmet Dermatol
Smith L, López-Gil JF, Rahmati M, Gawronska J, Ravindran R.   +4 more
europepmc   +1 more source

Dual-Toxin-Producing <i>Clostridium botulinum</i> Strain Isolated from a Foodborne Botulism Case in Korea: Genomic and Functional Insights. [PDF]

Toxins (Basel)
Choi ES, Choi CH, Jeon JH, Kim SH, Song HJ, Yi H, Rhie GE, Chung YS.   +7 more
europepmc   +1 more source

RelabotulinumtoxinA, a Ready-to-Use Formulation Neuromodulator Manufactured with PEARL™ Technology to Maintain High Biological and Specific Activity. [PDF]

Toxins (Basel)
Ståhl U, Lekholm E, Hamnevik E, Fredriksson R, Shridharani SM, Taghetchian K, Cohen JL, Nestor MS, Liljegren Sundberg Å.   +8 more
europepmc   +1 more source